Pioneers and Innovators of Peptide Science and Research

Why these four names matter

Peptides are everywhere in modern medicine — from insulin to the GLP-1 drugs dominating headlines — but that prominence is recent, and it rests on decades of foundational work. Three problems had to be solved before peptides could become useful: someone had to figure out how to reliably build them, someone had to discover what the body's natural peptides actually do, and someone had to engineer them into practical, long-lasting drugs. The four researchers profiled here each cracked one of those problems.

Bruce Merrifield solved the making. Roger Guillemin and Andrew Schally, working as rivals, solved the understanding — revealing that the brain speaks to the body through tiny peptide hormones. Richard DiMarchi, a generation later, solved the translation, turning peptide chemistry into medicines used by millions. Read together, their careers trace the entire arc of how peptides went from an intractable chemical puzzle to one of the most important classes of drugs we have. For the underlying chemistry, our primer on what peptides are and how they compare to proteins, bioregulators, biologics, and small molecules is a useful companion.

Bruce Merrifield: the man who made peptides buildable

Before Bruce Merrifield, synthesizing a peptide of any meaningful length was a punishing ordeal. Each amino acid had to be added in solution, and after every single coupling step the growing chain had to be laboriously isolated and purified before the next amino acid could be attached. Yields dropped with every step, and building anything longer than a short chain could take a chemist months of painstaking work with no guarantee of success. Peptide synthesis was less a routine technique than a heroic feat.

In the early 1960s, working at what is now Rockefeller University, Merrifield had a deceptively simple idea that changed everything: what if you anchored the first amino acid to a tiny insoluble bead — a solid support — and then built the chain outward from there? Because the growing peptide stayed attached to the bead, excess reagents and byproducts could simply be washed away after each step, no isolation required. Add an amino acid, wash, add the next, wash, and repeat. The method he called solid-phase peptide synthesis (SPPS) turned an artisanal ordeal into a systematic, repeatable cycle.

The consequences were enormous. SPPS was fast enough and reliable enough to be automated — Merrifield helped build one of the first peptide synthesizer machines — and it scaled to targets that had been unthinkable, including the synthesis of the enzyme ribonuclease, a protein of over a hundred amino acids. Nearly every research peptide made today, and much of the peptide-drug industry, traces its methodology back to his insight. In 1984 he was awarded the Nobel Prize in Chemistry for developing chemical synthesis on a solid matrix.

Guillemin and Schally: the great hormone race

While Merrifield was solving how to build peptides, two other researchers were locked in one of the most famous rivalries in science, racing to discover what the body's own peptides do. Roger Guillemin and Andrew Schally both set out to prove a then-controversial idea: that the hypothalamus, a small region at the base of the brain, controls the pituitary gland — and thus much of the body's hormonal system — by releasing tiny peptide signaling molecules. The problem was that these hormones existed in almost impossibly small quantities, forcing both teams to process staggering amounts of animal tissue to isolate even a trace.

The competition between their labs was intense and lasted years, but it was extraordinarily productive. Their combined work established that the brain governs the endocrine system through peptide hormones, founding the field now known as neuroendocrinology. In 1977 they shared the Nobel Prize in Physiology or Medicine — together with Rosalyn Yalow, honored separately for the radioimmunoassay technique that made measuring these vanishingly small hormones possible in the first place.

Andrew Schally: peptide hormone discovery

Andrew Schally's work centered on isolating and determining the structures of hypothalamic hormones — most notably thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH, also called LHRH). Crucially, Schally did not stop at discovery: he pursued the therapeutic potential of these peptides, and analogs of GnRH became real medicines. Long-acting GnRH agonists are used to treat hormone-sensitive conditions including prostate cancer, a direct clinical payoff from his basic research. His career is a model of how understanding a natural peptide can lead, step by step, to a drug.

Roger Guillemin: peptide endocrinology pioneer

Roger Guillemin, working at institutions including the Salk Institute, was a driving force in isolating TRH and GnRH and is especially associated with the discovery of somatostatin, a peptide that inhibits growth hormone release and has been developed into analogs used to treat certain tumors and hormonal disorders. Guillemin helped define the very concept of the brain as an endocrine organ that speaks in peptides. His broader legacy is the framework of neuroendocrinology itself — the recognition that small peptides are master regulators sitting at the top of the body's control hierarchy.

Richard DiMarchi: turning peptides into medicine

Discovery and synthesis made peptides possible; Richard DiMarchi is among those most responsible for making them into practical, widely used drugs. A chemist who spent much of his career bridging industry and academia — with major roles at Eli Lilly and later as a distinguished professor at Indiana University — DiMarchi specialized in the difficult art of engineering natural peptides into molecules with the stability, potency, and dosing properties that real medicines require.

His fingerprints are on some of the most important metabolic drugs of the modern era. He was central to the development of engineered insulin analogs — reworking the insulin molecule so it could act faster or last longer than the natural hormone — which transformed diabetes care. Later, he became a leading figure in the science of incretin therapies, the class that includes GLP-1-based drugs, and in the design of multi-receptor agonist peptides that hit more than one target at once to amplify metabolic benefit.

That last idea — a single peptide engineered to activate multiple receptors — underpins the newest generation of metabolic medicines and helped set off the current wave of interest in peptides for weight and glucose control. For the biology behind these drugs, see how GLP-1 works for weight loss, the overviews of semaglutide and tirzepatide, and the comparison of tirzepatide vs semaglutide. DiMarchi's career is the clearest demonstration that peptides, once merely interesting, could become commercially and clinically dominant.

The through-line to peptides today

Placed side by side, these four careers form a single continuous story. Merrifield made peptides buildable. Guillemin and Schally revealed what natural peptides do and why they matter. DiMarchi showed how to engineer them into medicines that reach millions of people. Each stage depended on the one before it — you cannot design a peptide drug without being able to synthesize peptides, and you cannot know which peptides to design without understanding their biology.

The momentum they created is still accelerating. The same foundations now power the push toward oral peptide delivery, long-acting peptide formulations, nasal peptide delivery, and the broader race to replace injectable peptides. The scientists profiled here would recognize the tools; the scale of what those tools now enable is their lasting legacy.